Arise Clinical Trial

CLINICAL TRIAL ENROLLING PATIENTS WITH IDIOPATHIC HYPERSOMNIA AND NARCOLEPSY TYPE 2

Arise Clinical StudyBalance Therapeutics is evaluating an investigational new drug BTD-001, to treat excessive daytime sleepiness in individuals diagnosed with idiopathic hypersomnia (IH) or narcolepsy type 2 (Na-2). A Phase 2 clinical trial is currently enrolling Na-2 subjects at 26 investigational centers in the United States. Individuals currently diagnosed as “IH” who may have previously been diagnosed as narcolepsy may also qualify. For more information regarding the study and participating site locations, and if you are interested in participating in this trial, please visit the website www.arisestudies.com.

Background:

Recent research published by a team from Emory University in Atlanta, Georgia has demonstrated that the excessive daytime sleepiness in many individuals diagnosed with idiopathic hypersomnia (IH) and narcolepsy type 2 (narcolepsy without cataplexy; Na-2) is driven by accumulation of a naturally occurring substance, yet to be identified, that increases the function of the sleep promoting neurotransmitter γ (gamma)-amino-butyric acid (i.e., GABA) in the brain. 

The investigational drug BTD-001 is known to suppress GABA activity. BTD-001 is therefore targeted more directly at emerging mechanisms thought to cause the excessive sleepiness of many patients diagnosed with IH and Na-2. It is also unique from current FDA approved therapeutic approaches for alleviating the excessive daytime sleepiness in individuals diagnosed with IH and Na-2.

To learn more information about the clinical trial and see if you might qualify, please visit the website arisestudies.com.

 

arise

 

Save

Share Post
FacebookTwitterLinkedInEmailShare

SomnusNooze Home Page

SomnusNooze Editions/Archives
Disclaimer

The contents of this website, including text, graphics and other material, are for informational purposes only. This website is not intended to be a substitute for professional legal or medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Always consult your own attorney or other legal advisor with any legal questions you may have. The Hypersomnia Foundation does not recommend or endorse any specific tests, physicians, lawyers, legal advisors, products, procedures, opinions or other information referenced on this website. Reliance on any information on this website is solely at your own risk.

The Hypersomnia Foundation makes no representations or warranties about the satisfaction of any government regulations requiring disclosure of information on prescription drug products. In no event shall The Hypersomnia Foundation be liable for any damages (including without limitation incidental and consequential damages) or costs (including without limitation attorney’s fees) based on any claim arising from the use of this website and/or its content.